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This BMJ Rapid Recommendation 
article is one of a series that 
provides clinicians with trustworthy 
recommendations for potentially 
practice changing evidence. 
BMJ Rapid Recommendations 
represent a collaborative effort 
between the MAGIC group (http://
magicproject.org/) and The 
BMJ. A summary is offered here 
and the full version including 
decision aids is on the MAGICapp 
(https://app.magicapp.org), for all 
devices in multilayered formats. 
Those reading and using these 
recommendations should consider 
individual patient circumstances, 
and their values and preferences 
and may want to use consultation 
decision aids in MAGICapp to 
facilitate shared decision making 
with patients. We encourage 
adaptation and contextualisation 
of our recommendations to local or 
other contexts. Those considering 
use or adaptation of content may 
go to MAGICapp to link or extract 
its content or contact The BMJ for 
permission to reuse content in this 
article.
ABSTRACT
Clinical question Recent 15-year updates of sigmoidoscopy screening trials provide new evidence on the 
effectiveness of colorectal cancer screening. Prompted by the new evidence, we asked: “Does colorectal cancer 
screening make an important difference to health outcomes in individuals initiating screening at age 50 to 79? 
And which screening option is best?”
Current practice Numerous guidelines recommend screening, but vary on recommended test, age and screening 
frequency. This guideline looks at the evidence and makes recommendations on screening for four screening 
options: faecal immunochemical test (FIT) every year, FIT every two years, a single sigmoidoscopy, or a single 
colonoscopy.
Recommendations These recommendations apply to adults aged 50-79 years with no prior screening, no 
symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 
15-year colorectal cancer risk below 3%, we suggest no screening (weak recommendation). For individuals with an 
estimated 15-year risk above 3%, we suggest screening with one of the four screening options: FIT every year, FIT 
every two years, a single sigmoidoscopy, or a single colonoscopy (weak recommendation). With our guidance we 
publish the linked research, a graphic of the absolute harms and benefits, a clear description of how we reached 
our value judgments, and linked decision aids.
How this guideline was created A guideline panel including patients, clinicians, content experts and 
methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy 
guidelines. A linked systematic review of colorectal cancer screening trials and microsimulation modelling were 
performed to inform the panel of 15-year screening benefits and harms. The panel also reviewed each screening 
option’s practical issues and burdens. Based on their own experience, the panel estimated the magnitude of 
benefit typical members of the population would value to opt for screening and used the benefit thresholds to 
inform their recommendations.
The evidence Overall there was substantial uncertainty (low certainty evidence) regarding the 15-year benefits, 
burdens and harms of screening. Best estimates suggested that all four screening options resulted in similar 
colorectal cancer mortality reductions. FIT every two years may have little or no effect on cancer incidence over 
15 years, while FIT every year, sigmoidoscopy, and colonoscopy may reduce cancer incidence, although for FIT 
the incidence reduction is small compared with sigmoidoscopy and colonoscopy. Screening related serious 
gastrointestinal and cardiovascular adverse events are rare. The magnitude of the benefits is dependent on the 
individual risk, while harms and burdens are less strongly associated with cancer risk.
Understanding the recommendation Based on benefits, harms, and burdens of screening, the panel inferred that 
most informed individuals with a 15-year risk of colorectal cancer of 3% or higher are likely to choose screening, and 
most individuals with a risk of below 3% are likely to decline screening. Given varying values and preferences, optimal 
care will require shared decision making.
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Visual summary of recommendation (1 of 5)
No screening FIT 
Every year
FIT 
Every two years
Sigmoidoscopy
Single
Colonoscopy
Single
StrongStrongFavours noscreening
Favours
screeningWeakWeak
We suggest no screening
StrongStrong WeakWeak
Interventions compared
Recommendations
Population
We suggest using a tool such as the QCancer® calculator 
to estimate the risk of colorectal cancer for each person 
in the next 15 years. This calculates risk, based on:
Understanding a person’s risk of cancer can help to 
determine the benefits and harms of different screening 
tests for their individual situation.
Faecal testing 
with a faecal 
immunochemical 
test (FIT) every 
year
Faecal testing 
with a faecal 
immunochemical 
test (FIT) every 
two years
Endoscopic 
examination of 
only the lower 
part of the colon
Endoscopic 
examination of 
the entire colon
Favours no
screening
Favours
screening
Colonoscopy offered if FIT 
or sigmoidoscopy positive
People with an estimated 15 year 
risk of colorectal cancer below 3%
We suggest screening with one 
of the four screening options
People with an estimated 15 year 
risk of colorectal cancer above 3%
Estimating risk
Healthy adults with no
history of screening
Aged 50 to 79 Age
Smoking status Medical and family history
BMISex Ethnicity
Link to QCancer®
calculator qcancer.org/15yr/colorectal/
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Visual summary of recommendation (2 of 5)
For a person with a 2% risk of colorectal cancer within 15 years
Screening options
Visit the MAGICapp multiple 
comparison tool to compare 
and choose options
Evidence summaries
Screening options should 
be chosen in shared decision 
making, based on a person’s 
individual risk of cancer
Colorectal cancer mortality
No screening
FIT every
year
Sigmoidoscopy
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two years
Colonoscopy
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3
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Evidence quality (GRADE score) Low
Colorectal cancer incidence
No screening
FIT every
year
Sigmoidoscopy
FIT every
two years
Colonoscopy
20
17
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13
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Evidence quality (GRADE score) Low
One or more colonoscopies
No screening
FIT every
year
Sigmoidoscopy
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two years
Colonoscopy
0
300
159
203
1000
Events per 1000 people
Evidence quality (GRADE score) Low*
Two or more colonoscopies
No screening
FIT every
year
Sigmoidoscopy
FIT every
two years
Colonoscopy
0
66
57
54
68
Events per 1000 people
Evidence quality (GRADE score) Low
* High quality for colonoscopy
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Key practical issues
While most of the evidence relates to people aged 50-79, 
these recommendations may also apply to those aged below 
50. However, as cancer risk is usually very low in this group, 
few people will have a 15 year colorectal cancer risk over 3%
Other ages
The panel found convincing evidence that people’s values and 
preferences on whether to test and what test to have varies 
considerably, and this is one factor driving a weak 
recommendation
Values and preferences
FIT Sigmoidoscopy
Done at home every year or every 
two years for 15 years
Done once in 15 years at an outpatient clinic/hospital
Stool from one bowel movement 
is collected with a stick and 
mailed for analysis
Preparation with bowel enema 
on the day of the procedure. 
Sometimes combined with 
oral laxatives
Preparation with oral laxatives 
starting the day before procedure
Individuals with a positive test are offered colonoscopy
Usually performed with no 
sedation, so no recovery time 
necessary after procedure
Often performed under 
conscious sedation. Also 
performed under general 
anesthesia or with no sedation
Most individuals will experience 
no or only mild pain during and 
shortly after the procedure, but 
some will experience moderate 
to severe pain
If sedation or anesthesia is used, 
recovery time will be needed 
after the procedure
If performed without sedation, 
the majority of individuals will 
experience no or only mild pain 
during and shortly after the 
procedure, but some will 
experience moderate to 
severe pain
Colonoscopy
Preparation
During the
process
Afterwards
Timing
Visual summary of recommendation (5 of 5)
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What is the role of colorectal cancer screening with 
faecal immunochemical testing (FIT), flexible sig-
moidoscopy or colonoscopy for people aged 50 to 79 
years?
Recent updates to three of the major trials on sigmoidos-
copy screening were published in 2017-19.1-3 The trials 
provide evidence on screening effectiveness for up to 15 
years after a single sigmoidoscopy. Two of these trials 
reported a reduction in colorectal cancer mortality and 
incidence with sigmoidoscopy screening in men, but only 
a small or no reduction in women.2 3 This has sparked 
interest in whether women and men should be screened 
differently, and in which test is better for screening for 
colorectal cancer. We concluded that this new evidence 
could change current recommendations. Our recommen-
dations are based on systematic reviews of benefits and 
harms of screening and, in the absence of randomised 
trial results for FIT and colonoscopy, on microsimulation 
modelling.4 5
The lifetime risk of colorectal cancer is approximately 
5% in many Western countries, with varying risk in dif-
ferent geographical areas.6 It is one of the most common 
cancers in both men and women. An individual’s risk of 
cancer depends on age, sex, and genetics, and may be 
influenced by lifestyle factors such as alcohol intake, 
smoking, physical activity, and diet.7 The five-year sur-
vival of colorectal cancer is 65%, with higher survival 
HOW THESE RECOMMENDATIONS WERE CREATED
Our international panel included patient partners 
(individuals with experience of colorectal cancer 
screening), general practitioners, general 
internists, gastroenterologists, content experts 
(those conducting primary studies in colorectal 
cancer screening and immersed in the field), 
methodologists, and a nurse practitioner. No 
panel member reported financial conflicts of 
interest. Intellectual and professional conflicts 
were minimised and managed (see appendix 2 
for details of panel members and their competing 
interests). The panel initially decided on the 
scope of the recommendation and the outcomes 
that they considered most important for 
individuals considering screening.
It was out of the scope for these guidelines 
to address all existing screening options. The 
panel decided to include the most commonly 
used options with the most solid evidence base. 
Randomised trials with sufficient follow-up for 
estimation of screening benefits have studied 
only sigmoidoscopy and guaiac faecal occult 
blood testing (gFOBT). However, today the most 
widely practiced screening tests are faecal 
immunochemical test (FIT) and colonoscopy.8 9 
FIT has a higher sensitivity and is more 
acceptable than gFOBT, and most screening 
programmes using faecal blood testing have 
changed to FIT. The panel therefore chose not 
to include guidance on gFOBT.16 17 The panel 
requested the best evidence for four screening 
options: FIT every year, FIT every two years, a 
single sigmoidoscopy, and a single colonoscopy. 
For each option, the panel chose a 15-year 
time frame because that corresponds to the 
longest follow-up in the existing randomised 
sigmoidoscopy screening trials. FIT tests with 
a cut-off of 20 μg Hb/g faeces were considered 
positive.
The panel identified the following important 
outcomes: all-cause mortality, colorectal cancer 
mortality, colorectal cancer incidence, colorectal 
bleeding and perforation, other serious adverse 
events, and number of individuals needing at 
least one, two, or more colonoscopies. The panel 
also identified the following practical issues that 
could influence decisions regarding screening: 
emotional stress and anxiety related to a positive 
test, pain, discomfort, and absence from work 
related to screening procedures.
To inform the recommendations, the panel 
asked the following questions:
1. What benefit (reduced colorectal cancer 
mortality or incidence) would most individuals 
require to undergo colorectal cancer screening? 
In other words, what are peoples’ anticipated 
values and preferences in trading off benefits 
versus burdens and harms?
2. In healthy individuals aged 50-79 years, 
what are the benefits, harms, and burdens 
over a 15 year period of screening with faecal 
testing every year or every two years, or a single 
sigmoidoscopy or colonoscopy, compared with 
no screening or with one another?
Parallel teams conducted systematic reviews 
and microsimulation modelling to inform the 
panel (described in detail in appendices 3-5 and 
the linked articles4 5).
The systematic review of values and 
preferences did not provide clear evidence of 
what benefit most individuals would require to 
undergo screening. The panel therefore identified 
thresholds for anticipated magnitude of benefit 
people would require and used this as guidance 
when deciding on the recommendations (see box 
2 and appendix 3 for details).
A dedicated team performed a systematic 
review and network meta-analysis of randomised 
trials evaluating benefits and harms of colorectal 
cancer screening (see linked article5).
No randomised trials have addressed the 
effectiveness of FIT and colonoscopy screening, 
so the panel requested microsimulation 
modelling to estimate the benefits, burdens, and 
harms of the four screening options compared 
with no screening over a 15 year period (see 
linked article4). The panel also requested a 
systematic survey of reviews of screening-related 
burdens and harms that included observational 
studies designed to evaluate harms after 
screening, because data from randomised trials 
were limited (see appendix 4).
The panel asked the teams to explore potential 
subgroup effects for screening benefits by sex 
and of screening-related harms by age.
The panel acknowledged that the risk of cancer, 
and thus the magnitude of expected benefits 
and harms, varies substantially in the target 
population for these recommendations. The 
panel decided to base the recommendation on 
an individual estimation of colorectal cancer 
risk over 15 years. Details about the choice of 
calculator for the prediction of individual risk is 
provided in appendix 6.
The panel found that the thresholds of required 
benefit for either colorectal cancer mortality or 
incidence met at approximately 3% risk for all 
screening options.
Figure 1 shows the benefits of the different 
screening tests per 1000 screened, depending 
on the 15-year risk of colorectal cancer.
The panel followed BMJ Rapid 
recommendations procedures for creating 
a trustworthy recommendation, including 
the GRADE approach (see appendix 7). The 
panel met by videoconferences to discuss the 
evidence and formulate recommendations,18 19 
and considered the balance of benefits, harms, 
and burdens of the screening options and no 
screening, the certainty of the evidence for each 
outcome, expected variations in individuals’ 
values and preferences, as well as practical 
issues.20 Recommendations using GRADE can 
be strong or weak, for or against a course of 
action.18 The panel made the recommendation 
from an individual perspective, assuming that 
all options were available and affordable. The 
recommendation does not take a public health, 
societal, or health payer perspective. Healthcare 
systems can adapt these recommendations 
by including costs and other key issues of 
relevance, contextualised to national and local 
circumstances.21
The number of individuals in need of two 
or more colonoscopies presented in this 
guidance differ slightly from the numbers 
presented to the panel in the process of making 
the recommendations (see appendix 3). The 
difference was due to a coding mistake that has 
been corrected. The panel decided that these 
changes did not alter the final recommendations.
One of the content experts on the panel did 
not wish to be a co-author of this article due to 
disagreement with the approach and the final 
recommendations. Two panel members (ILV 
and DAC) has strong reservations concerning 
the use of thresholds for the recommendations, 
due to limitations in the way the thresholds 
were determined. Box 2 presents the process of 
developing the thresholds and its limitations.
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adenomas). The awareness of colorectal cancer screening 
has increased from the early 2000s, and most European 
countries, North America, and parts of South America, 
Asia, and Oceania have implemented or are planning 
implementation of screening (table 1).11
This guideline provides recommendations for the 
most widely used screening tests worldwide. It is the 
first guideline on colorectal cancer screening to provide 
observed in localised disease. All patients with colorec-
tal cancer are offered surgical treatment. In addition, 
patients with advanced disease undergo chemotherapy 
or radiation.
Screening aims at reducing colorectal cancer mortality 
and/or incidence by detecting cancer early (by regular 
testing for faecal blood), or prevention of cancer devel-
opment (by detecting and removing cancer precursors, 
Table 1 | Major guideline recommendations addressing colorectal cancer screening for average risk populations; all recommend screening from a certain age, and 
some recommend against screening in older age; none explicitly incorporates shared decision making based on individual risk and perceived benefits, harms, and 
burdens. For simplicity, the table includes only the preferred test or first-tier recommendations
Organisation Screening age GRADE strength of recommendation Recommended test and timing
American College of Gastroenterology, 2009 Start 50 years Strong, for screening Colonoscopy every 10 years
American College of Physicians, 2015* Screening for 50-75 years  
Not recommended >75 years
N/A High sensitivity gFOBT or FIT every year
gFOBT or FIT every 3 years or 
Sigmoidoscopy every 5 years
Colonoscopy every 10 years
US Preventive Services Task Force, 2016 Screening for 50-75 years 
For 76-85 years, an individual 
decision
N/A gFOBT or FIT every year
FIT-DNA every 1-3 years
FIT every year or 
Sigmoidoscopy every 10 years
Sigmoidoscopy every 5 years
Colonoscopy every 10 years
CT colonography every 5 years
National Comprehensive Cancer Network 
Guidelines, 2017
Screening for 50-75 years  
For 76-85 years, an individual 
decision
N/A Colonoscopy every 10 years
gFOBT or FIT every year
Faecal DNA test every 3 years
Sigmoidoscopy every 5-10 years ± gFOBT or FIT every 3 years
CT colonography every 5 years
United States Multi-Society Task Force of Colorectal 
Cancer Guidelines, 2017
Screening for age 50-75 years 
For 76-85 years, consider for 
those without prior screening
For screening: strong for 50-75, weak for 76-85 
years
FIT every year
Colonoscopy every 10 years
American Cancer Society, 2018 Screening from 45 years 
Screening for 50-75 years 
For 76-85 years an individual 
decision based on preference, 
life expectancy, and overall 
health
For screening: weak for 45-49, strong for 50-75, 
weak for 76-85 years
High sensitivity gFOBT or FIT every year
Multi-targeted stool DNA every 3 years
Colonoscopy every 10 years
CT colonography every 5 years
Sigmoidoscopy every 5 years
Canadian Task Force on Preventive Health Care, 
2016
Screening for 50-74 years  
Not recommended for >75 
years
For screening: weak for 50-59, strong for 60-74  
Weak against screening >75 years 
gFOBT or FIT every 2 years
Sigmoidoscopy every 10 years
German Guideline Program in Oncology, 2019 Start 50 years N/A Colonoscopy every 10 years
Spanish Society of Medical Oncology, 2014 Screening for 50-74 years N/A FIT every two years
gFOBT every 1-2 years
Sigmoidoscopy every 5 years
Colonoscopy every 10 years
National screening programmes in Sweden, New 
Zealand and United Kingdom†
Screening for 60-74 years N/A FIT every 2 years
National screening programmes in Denmark and 
France
Screening for 50-74 years N/A FIT every 2 years
Korean Guidelines for Colorectal Cancer Screening 
and Polyp Detection, 2012
Start 50 years Strong, for screening Colonoscopy every 5 years
Chinese Society of Gastroenterology, 2014 Screening for 50-74 years N/A FIT and questionnaire every 3 years
Updated Asia Pacific Consensus Recommendations 
on colorectal cancer screening, 2015
Screening for 50-75 years N/A FIT, interval not mentioned
National Guidelines for Colorectal Cancer Screening 
in Saudi Arabia, 2015
Screening for 45-70 years  
Not recommended >70 years
Strong, for screening 54-70 
Weak against screening >70 years 
Colonoscopy every 10 years
World Gastroenterology Organisation, 2007 Start 50 years N/A Colonoscopy every 10 years
NHMRC, Clinical Guidelines for Prevention, Early 
Detection and Management of Colorectal Cancer, 
Australia, 2017
Screening for 50-74 years N/A FIT every 2 years
National guideline in Japan Start 40 years N/A FIT every year
gFOBT = guaiac faecal occult blood test. FIT = faecal immunochemical test.
The recommendations listed is a selection of recommendations identified through two systematic surveys: one found 15 colorectal cancer screening guidelines published in English between 2007 and 2017 (6 
from North America, 4 from Europe, 5 from Asia)8; the other survey in high income countries found another 19 guidelines.9
*Update of guideline in progress (Amir Qaseem, ACP, personal communication).
†In addition to FIT screening every two years, a one-time sigmoidoscopy is currently being rolled out for people at age 55 in the UK.10
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explicit judgments of values and preferences, and bas-
ing the recommendations on absolute benefits, harms, 
and burdens of screening in a 15 year period. Within 
the population under consideration for this guideline, 
there are groups with different risks of developing colo-
rectal cancer, ranging from less than 1% to more than 
15% over 15 years. Most people, however, will be in the 
range from 1% to 7%. This is the first guideline that gives 
recommendations based on individual cancer risk. The 
guideline also includes practical issues important for the 
screening decision and decision aids for use in the clini-
cal encounter.
The main infographic provides an overview of mod-
elled estimates of the absolute benefits and harms of 
screening, when the 15-year risk of colorectal cancer is 
2%, 3%, or 4%, and assuming 100% adherence to all 
screening tests, work-up, and surveillance colonoscopies 
in a 15 year period. A microsimulation model informed 
by randomised trials and observational studies provided 
all estimates of benefit and harm.4 Box 1 shows all evi-
dence linked in this Rapid Recommendation package. 
Table 2 shows any new evidence that has emerged after 
initial publication of these recommendations.
Current practice
What is recommended?
Some countries have systematic, population based, 
screening programmes in which presumed asymptomatic 
people are invited for screening. In others, including the 
US, widespread opportunistic screening is common 
(depending on initiatives from patients or clinicians), 
although in some settings there are comprehensive 
screening outreach programmes, such as within the Kai-
ser Permanente health system.12
Most guidelines recommend screening starting at age 
50 years, when the risk of cancer in the next 15 years is 
typically 1-2% (in European and North American popu-
lations).13-15 Screening is performed with many different 
tests and combination of tests, with different frequencies 
and in different age groups. However, the most common 
screening options are faecal testing, sigmoidoscopy, and 
colonoscopy. Which test is used varies due to different 
priorities and different interpretation of the existing evi-
dence by guideline developers and screening providers, 
but also because of differences in peoples’ values and 
preferences. 
Current guidelines provide the same recommendations 
for all individuals above a certain age and do not account 
for individual differences in cancer risk. Table 1 presents 
a summary of some of these recommendations based on 
two surveys published in 2018.8 9
The evidence
Evidence summaries are available for those at 2%, 3%, 
and 4% risk at the start of their screening (see main info-
graphic). Fig 2 provides an overview of the data sources 
used to inform this guideline.
How do people value colorectal cancer screening?
People’s view on the net benefit of screening varies sub-
stantially.22 23 We know this because our literature review 
found a variety of different recommendations (see table 
1), limited uptake of screening in practice (see box 2) and 
variation in studies of people’s values and preferences.
The literature review of studies on values and prefer-
ences did not identify evidence informing the magnitude 
of benefit people would require to undergo colorectal can-
cer screening. Therefore, before reviewing the evidence of 
screening benefits, the panel used their own experience 
to hypothesise what benefit of screening they thought 
people would require to undergo screening. This process 
helped minimise the influence of prior guideline recom-
mendations, or potential preconceived beliefs of the net 
benefit of screening, on the panelists’ view on the thresh-
old of required benefits. (See box 3 and appendix 3 for 
details on this process).
Panel members’ views varied, but, after discussion, 
we decided to use the following thresholds of benefits, 
at which the panel believed around half of informed indi-
viduals would choose screening:
•   Sigmoidoscopy or colonoscopy if the screening could 
reduce colorectal cancer mortality and/or incidence 
by 10 or more per 1000 screened over a 15 year 
period
•   FIT if the screening could reduce colorectal cancer 
mortality and/or incidence by 5 or more per 1000 
screened over a 15 year period. (Lower threshold 
because the panel perceived the burdens of testing 
as smaller for FIT than for sigmoidoscopy or 
colonoscopy.)
What are the benefits of colorectal cancer screening?
Randomised trials have addressed screening with sig-
moidoscopy and gFOBT and provide high to moderate 
certainty evidence for screening effectiveness: sigmoidos-
copy reduces colorectal cancer mortality and incidence 
after 15 years of follow-up, and gFOBT every year or every 
Box 1 | Linked resources for this BMJ Rapid 
Recommendations cluster
• Helsingen LM, Vandvik PO, Jodal HC, et al. Colorectal 
cancer screening with faecal immunochemical testing, 
sigmoidoscopy or colonoscopy: a clinical practice 
guideline. BMJ 2019;367:l5515.
 – Summary of the results from the Rapid 
Recommendation process
• Jodal HC, Helsingen LM, Anderson JC, et al. Colorectal 
cancer screening with faecal testing, sigmoidoscopy or 
colonoscopy: a systematic review and network meta-
analysis. BMJ Open 2019;0:e032773.5
 – Review of all available trials that assessed colorectal 
cancer screening
• Buskermolen M, Cenin DR, Helsingen LM, et al. Colorectal 
cancer screening with faecal immunochemical testing, 
sigmoidoscopy or colonoscopy: a microsimulation 
modelling study. BMJ 2019;367:l5383.4
 – Modelling study of different modalities for colorectal 
cancer screening
• MAGICApp (https://app.magicapp.org/public/guideline/
EQNVKj)
 – Expanded version of the results with multilayered 
recommendations, evidence summaries, and decision 
aids for use on all devices
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two years reduces colorectal cancer mortality but has lit-
tle or no impact on cancer incidence. Neither sigmoidos-
copy nor gFOBT affects all-cause mortality. For details, 
see the linked review.5
Because of lack of trial data for FIT and colonoscopy, 
we used a microsimulation model to provide ultimate 
estimates for clinical decision making. The model has 
been validated against the results from the trials of sig-
moidoscopy and gFOBT, but due to the assumptions 
inherent in the model, it can only provide estimates of low 
certainty. The estimates of colorectal cancer incidence 
and mortality reduction from the model are higher than 
those observed in randomised screening trials. Our model 
is based on 100% adherence to screening, work-up and 
surveillance colonoscopies, whereas the trial estimates 
reflect substantially lower rates of adherence (see box 2). 
A linked article provides details of the modelling.4
All the modelling data are of low certainty. It is a useful 
indication, but there is a high chance that new evidence 
will show a smaller or larger benefit, which in turn may 
alter these recommendations. Compared with no screen-
ing, the model estimates that:
•   Colorectal cancer mortality may be reduced similarly 
by all four screening tests
 – FIT every two years (relative risk 0.5)
 – FIT every year (relative risk 0.41)
 – Single sigmoidoscopy (relative risk 0.48)
 – Single colonoscopy (relative risk 0.37)
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Fig 1 |  Number of colorectal cancer (a) deaths and (b) cases prevented by different screening options per 1000 screened 
individuals, stratified by individuals’ 15-year risk of colorectal cancer. 
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DATA SOURCES
Use this information to gauge how similar your patients’ conditions are to 
those of people included in the evidence base for these recommendations
BENEFITS REQUIREDMODELLING: 15-YEAR PREDICTIONS
RECOMMENDATIONS
Adherence to
screening and follow-up
100%
Natural history of adenoma and 
preclinical cancer development.
Calibrated to observational data 
and trial data
KEY ASSUMPTIONS SCREENING OPTIONS
Age
range
50 to 79 years Timeframe 15 years
FIT every two years FIT every year
Sigmoidoscopy once Colonoscopy once
Interventions
FIT EVERY YEAR OR EVERY TWO YEARS
Colorectal cancer mortality
and/or incidence reduction of 
5 per 1000 screened (0.5%)
SIGMOIDOSCOPY OR COLONOSCOPY
Colorectal cancer mortality 
and/or incidence reduction of 
10 per 1000 screened (1%)

Every two years
(2 to 9 rounds) 4
Every year
(max. 11 rounds)  
1
Once 3 
Twice 1 
FOLLOW-UP DURATION (years)
10 20 30
Guaiac faecal 
occult blood test 4
Sigmoidoscopy 4
TRIAL CHARACTERISTICS
PATIENT CHARACTERISTICS
Age range:
45 to 80
Age range:
50 to 74 
Sex (median): 
52% women (52 to 52%)
Screening adherence (median):
68% of screened participants
(60 to 90%)
Screening adherence (median):
68% of screened participants
(58 to 84%)
Sex (median): 
50% women (50 to 51%)
Matched cohort study 1 
Sex:
58% women
Age range:
66 to 95
Intervention: Outpatient colonoscopy 
LIFE TABLES, NORWAY 2007
NORWEGIAN CANCER REGISTRY
Colorectal cancer:
Incidence Stage distribution Survival
FAECAL IMMUNOCHEMICAL TEST (FIT)
Cross-sectional study 1 
Intervention: FIT with consecutive colonoscopy
SIGMOIDOSCOPY AND COLONOSCOPY
Systematic review 1 
Intervention: Tandem colonoscopy
SCREENING FREQUENCY SCREENING FREQUENCY
Number of trials Number of participants
11.4
Median
30.0
Min
14.8
Median
16.8
Median
17.1
Median
19.5
Median
15.5
Mean
17.0
Max
OBSERVATIONAL DATARANDOMISED CONTROLLED TRIAL DATA
SENSITIVITY AND SPECIFICITY
SERIOUS ADVERSE EVENTS
DEMOGRAPHY
Estimated by
guideline panel
Fig 2 |  Data sources included in the modelling study of the absolute benefits and harms of different colorectal cancer screening options.
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•   Colorectal cancer incidence
 – May be reduced little or not at all by FIT every two 
years (relative risk 0.95)
 – FIT every year may achieve a small reduction 
(relative risk 0.85)
 – May be reduced by a single sigmoidoscopy (relative 
risk 0.73)
 – May be reduced by a single colonoscopy (relative 
risk 0.66).
There was no clinically relevant difference in all-cause 
mortality when comparing screening with no screening, 
or between the different screening options.4
Do the benefits differ by sex?
Based on the meta-analysis of randomised trial data, the 
panel believed the subgroup effect that sigmoidoscopy 
screening is more effective in men than women.5 They 
used criteria for credibility of subgroup effects to judge 
this.26 However, the relative effect differences of screening 
in men and women did not translate into an absolute dif-
ference to justify different recommendations for the sexes. 
Appendix 4 presents this evidence and a worked example.
Where did data on burdens and harms of screening and 
follow-up come from?
Number of colonoscopies needed was considered an 
important burden of screening by the panel. Colonos-
copies are performed either as the primary screening 
test, after a positive sigmoidoscopy or FIT screening, or 
as surveillance due to the finding of adenomas. No trial 
provides estimates of the number of individuals requiring 
colonoscopies after screening over a 15 year period. Our 
estimates are derived from the microsimulation model 
and are of low certainty. The model assigns every indi-
vidual with a high risk adenoma (several adenomas or an 
adenomas >10 mm diameter) to surveillance colonoscopy 
after three years, and thereafter repeated colonoscopies 
with intervals of three to five years (depending on the 
findings).4
The 15-year estimates for screening related mortality, 
risk of colorectal perforations and bleedings, other gas-
trointestinal adverse events, and cardiovascular adverse 
events are derived from additional modelling of a large 
cohort from a US registry.4 27 28 The estimates from this 
cohort study are consistent with the best current evidence 
regarding serious harms from screening (see appendix 
5). In the model, the harms are driven by the number of 
colonoscopies needed, and are of low certainty due to 
modelling of number of colonoscopies (see appendix 1 
for full evidence summaries).
Planned evaluation of harms by age
Limited data exists addressing harms of screening by age. 
The gastrointestinal adverse events from colonoscopy 
probably increase with age, but the absolute risk is still 
Box 2 | Screening uptake
Participation in systematic screening is often under 50%, 
but varies widely: 
• In screening programmes with faecal testing in Australia, 
Europe, America, and Asia, the participation rate varied 
between 16% and 68%.11
• In a European, population based, randomised trial of 
colonoscopy screening, participation rates were 61% in 
Norway, 40% in Sweden, 33% in Poland, and 23% in the 
Netherlands.24
• In another randomised trial comparing faecal 
immunochemical test (FIT) and colonoscopy in Spain, the 
rate of participation was higher in the FIT group (after one 
round) than in the colonoscopy group (34% v 25%).25
• Some organised efforts that incorporate screening 
outreach and follow-up have demonstrated screening rates 
of over 80%.12
Box 3 | Process and limitations of determining thresholds 
of benefits required to undergo screening
Process of determining a benefit threshold
The panel completed three surveys presenting different 
hypothetical screening scenarios. For each scenario, the 
panelists chose whether: almost all (>90%), most (75-90%), 
or the majority (50-75%) would choose or decline screening. 
The panelists responded according to their estimates 
of what most well informed people would choose (see 
appendix 3 for more details of this process).
• The first survey included hypothetical scenarios of 
colonoscopy screening with varying absolute risk 
reductions for colorectal cancer mortality (1, 10, 20, and 30 
per 1000 screened) over a 15 year period.
• The second survey focused on what benefit would be 
required to recommend one screening test over another.
• Initially, the panel chose the same benefit threshold 
for all tests. However, after reviewing the full evidence 
summaries (see main infographic), the panel felt that the 
burdens and harms of FIT were considerably smaller than 
for sigmoidoscopy or colonoscopy. The panel decided 
to undertake a third survey presenting scenarios of FIT 
screening with reductions in colorectal cancer mortality 
ranging from 1 to 10 per 1000 screened.
Limitations
There are several limitations related to the establishment of 
these thresholds
• First, because no direct evidence has addressed how much 
benefit people would require to be willing to undergo 
screening, the panel relied on indirect evidence and their 
experience in making their estimates.
• Second, the way the evidence is framed—for instance, 
for benefits of screening, one could say that colorectal 
cancer mortality was reduced from 2% to 1% over 15 
years or that the percentage of people who do not die from 
cancer increases from 98% to 99%—influences peoples’ 
decisions. We used only one method to present the 
benefits.
• Third, the first survey was based on a limited set of 
potential thresholds with large increments (1, 10, 20, or 30 
prevented deaths or cancers). Smaller increments might 
have led to a different choice—and may have been one 
factor in the different choice of thresholds for FIT.
• Fourth, the panel made a single recommendation at the 
“break-even point” where benefits and harms are closely 
balanced. The panel could have chosen to make additional 
recommendations at a very low risk (where almost all would 
choose not to screen), or a very high risk (where almost all 
would choose screening). The available evidence suggests, 
however, that there may be those who would decline 
screening even with a very large benefit, and those who 
would choose screening even with a very small benefit.
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very small in individuals above 75 years old. The panel 
therefore decided that these differences would not influ-
ence the recommendations (see appendix 5 for details).
Colorectal cancer risk prediction
A recent systematic review and an external validation 
study of colorectal cancer risk prediction models iden-
tified several prediction models, developed in different 
countries and with similar discrimination, as detailed in 
appendix 6.29 30 The QCancer was one of the best perform-
ing models for both men and women, with an area under 
the receiver operating curve (AUC) of 0.85 for women 
and 0.86 for men in the development cohort,31 and 0.66 
for women and 0.70 for men in the external validation 
cohort.29
The QCancer model was developed within a UK popula-
tion and may overestimate or underestimate risk for indi-
viduals from other countries with different distributions 
of risk factors and/or incidence of colorectal cancer. We 
nevertheless suggest this model because it is available as 
an online calculator; includes only risk factors available 
in routine healthcare; has been validated in a population 
separate from the derivation population; has reasonable 
discriminatory ability; and has a good fit between pre-
dicted and observed outcomes (calibration).29 31 In addi-
tion it is the only online risk calculator we know of that 
predicts risk over a 15 year time horizon.
Understanding the recommendations
If an individual’s estimated 15-year risk of colorectal can-
cer is 3% or more, the panel suggests screening with any 
one of the four options; if the estimated risk is below 3% 
the panel suggests no screening. These are weak recom-
mendations, which means that in the context of shared 
decision making, some people with a risk of over 3% are 
likely to decline screening, and some with a risk under 
3% will choose to screen.
•   Our recommendations apply to asymptomatic adults 
aged 50-79 years with a life expectancy of at least 15 
years. 
•   Our recommendations do not apply to people who
 – Have previously been screened
 – Have a history of polyps or colorectal cancer
 – Have inflammatory bowel disease
 – Have hereditary syndromes that increase the risk 
of colorectal cancer, such as Lynch syndrome and 
familial adenomatous polyposis.
Several factors influence individuals’ decisions 
whether to be screened, even when they are presented 
with the same information:
•   Variation in an individual’s values and preferences
•   A close balance of benefits versus harms and 
burdens (for example, for a baseline risk of 3%, FIT 
every two years results in five fewer deaths from 
colorectal cancer per 1000 screened versus three 
gastrointestinal or cardiovascular adverse events and 
246 needing at least one colonoscopy).
•   The estimates of both benefits and harms are 
associated with considerable uncertainty, as is the 
estimate of an individual’s risk over a 15 year time 
frame. 
The panel did not recommend any of the four screen-
ing options over any other. Clinicians should support 
each individual to choose their most suitable option. 
These recommendations are based on full adherence 
to screening and all potential work-up and surveillance 
colonoscopies in a 15 year period. With full adherence 
the options have similar reductions in colorectal cancer 
mortality, but different reductions in colorectal cancer 
incidence. The tests also have different burdens and 
practical issues. 
Some individuals may value a minimally invasive test 
such as FIT, and the possibility of invasive screening with 
colonoscopy might put them off screening altogether. 
Those who most value preventing colorectal cancer or 
avoiding repeated testing are likely to choose sigmoidos-
copy or colonoscopy. Fig 3 presents practical issues key 
to the screening decision.
How to estimate an individual’s 15-year colorectal 
cancer risk
We suggest the QCancer calculator for estimating 
the colorectal cancer risk (see main infographic). The 
calculator includes age, sex, ethnicity, smoking status, 
alcohol use, family history of gastrointestinal cancer, 
personal history of other cancers, diabetes, ulcerative 
colitis, colonic polyps, and body mass index. To mini-
mise the likelihood of misinterpretation and to facilitate 
shared decision making, the ideal setting for using the 
calculator may be a consultation with a healthcare pro-
vider.
If the predicted risk for a particular individual is, 
for example, 3.0%, the appropriate interpretation is: 
“In a group of 100 people with the same risk factors as 
you, 3 will develop colorectal cancer within the next 15 
years.”
As they age, people may revisit their decision
The most important risk factor for colorectal cancer 
screening is age. After age 50, colorectal cancer risk 
increases by 0.5-1.5% every five years for most peo-
ple.13 14 This translates to an additional reduction in 
colorectal cancers of 0-2 per 1000 screened individuals 
for FIT, and of 1-5 per 1000 for colonoscopy and sigmoi-
doscopy. The additional reduction in colorectal cancer 
mortality will be 1 per 1000 or smaller. Those who decide 
not to undertake screening but who think an additional 
benefit of this magnitude might change their decision, 
might consider reviewing their risk approximately every 
five years.
Public health implications
This guideline underlines that people need balanced 
information to decide whether they wish to screen for 
colorectal cancer, and public health efforts should focus 
on shared decision making for individuals who are eli-
gible for screening. Many healthcare systems use the 
uptake of colorectal cancer screening as a performance 
indicator.32 33 As many well informed individuals will 
choose to forego screening, discussion and information 
sharing on screening for colorectal cancer would be a 
better marker of care rather than uptake.
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TRAVEL TIME
& DRIVING
If sedated, not possible to 
drive directly aer procedure, 
need for transportation
Will not influence 
work/education
Can be done in the privacy of 
own home and fit into own 
schedule
Need to take time off work 
during preparation time and 
procedure day
Need to take time off work for 
procedure day
WORK &
EDUCATION
SOCIAL LIFE &
RELATIONSHIPS
Adverse effects are rare, but 
sedation may slightly increase 
risk of perforation of colon
Need for some recovery time 
aer procedure, dependent on 
level of sedation (no recovery 
necessary if no sedation)
ADVERSE EFFECTS,
INTERACTIONS &
ANTIDOTE
Help can be needed if 
eyesight or dexterity is poor
COORDINATION
OF CARE
RECOVERY &
ADAPTATION 
Stool from one bowel 
movement is collected by a 
stick and then mailed for 
analysis
Can be uncomfortable to 
access stool
PROCEDURE &
DEVICE
Bowel enema same day 
sometimes combined with 
cleansing of bowel with 
laxatives
Thin, flexible tube with a small 
camera is passed into the 
rectum and guided around in 
the lower part of the large 
bowel
Need for cleansing of bowel 
by specific preparation 
regime with laxatives starting 
the day before procedure
Thin, flexible tube with a small 
camera is passed into the 
rectum and guided around in 
the large bowel
Depending on country, 
region, clinic; different levels 
of sedation from light to deep 
sedation, or no sedation at all
TEST & VISIT
Done every or every two years 
at home
PRACTICAL ISSUES
MEDICATION
ROUTINE
Feacal testing Sigmoidoscopy Colonoscopy
Continue medication routine 
as prescribed
Some medicines, especially blood thinners, may be paused
Done once at an outpatient clinic/hospital
Individuals with a positive test will be referred for colonoscopy
No recovery time necessary
Should be near a toilet during preparation
Fig 3 |  Practical issues for the different methods for colorectal cancer screening
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Uncertainty
Only a few screening tests and intervals have been 
tested in randomised trials (once-only sigmoidoscopy 
and gFOBT every one or two years), but many different 
screening options are used in clinical practice. There are 
many uncertainties in terms of what is the most effective 
screening test or combination of tests, and at what age 
and interval they should be used. Some jurisdictions use 
combinations of screening tests; our guidelines do not 
address such combinations. We chose a 15 year time-
frame and do not provide guidance beyond that point. 
It is uncertain whether there is additional benefit in con-
tinued FIT screening beyond 15 years or in a repeated 
sigmoidoscopy or colonoscopy before or after 15 years.
We found evidence that the relative reductions in inci-
dence and mortality of colorectal cancer were smaller in 
women than in men after a single sigmoidoscopy, but the 
absolute effect differences were too small to warrant sex-
specific recommendations. Whether the effects of other 
screening tests differ by sex is unknown.
The process of making these recommendations was 
challenging, often with opposing views in the panel. 
Particular challenges were the lack of randomised trials 
for colonoscopy and FIT (which made us rely on modelled 
estimates of low certainty for screening benefit) and the 
uncertainty in people’s values and preferences.
Key research questions to inform decision makers and 
future guidelines include:
•   What are the population’s values and preferences 
regarding the magnitude of benefit needed to 
undergo screening, and the choice of screening test?
•   What are the benefits and harms of colonoscopy and 
FIT screening, and do the effects differ for men and 
women?
Updates to this article
Table 2 shows evidence that has emerged since the pub-
lication of this article. As new evidence is published, a 
group will assess the new evidence and make a judge-
ment on the extent it is expected to alter the recommen-
dation.
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